Are there any approved drugs that directly target the KRAS G12V mutation?

No FDA-Approved Drugs Directly Target KRAS G12V

Currently, there are no FDA-approved drugs that directly target the KRAS G12V mutation. The only approved direct KRAS inhibitors—sotorasib and adagrasib—are specific for KRAS G12C mutations and do not work against G12V 1, 2.

Current Treatment Landscape for KRAS G12V

Standard Therapy Approach

For patients with KRAS G12V-mutated cancers, treatment follows non-driver alteration guidelines:

For Non-Small Cell Lung Cancer:

• First-line: Standard platinum-based chemotherapy with or without immune checkpoint inhibitors 1, 3
• KRAS G12C inhibitors (sotorasib, adagrasib) are not effective for G12V mutations 1

For Colorectal Cancer:

• Standard chemotherapy regimens (FOLFOX, FOLFIRI, CapeOX) with or without bevacizumab 2
• Anti-EGFR antibodies (cetuximab, panitumumab) are contraindicated in any KRAS-mutant disease, including G12V 4, 5

Why G12C Inhibitors Don't Work for G12V

The approved KRAS G12C inhibitors function through covalent binding to the cysteine residue at position 12. KRAS G12V has valine (not cysteine) at this position, making these drugs mechanistically unable to bind 6, 7, 8.

Emerging Investigational Approaches

Pipeline Developments (Not Yet Approved)

RNAi-Based Therapy:

• EFTX-G12V: An EGFR-directed RNA interference molecule showing G12V selectivity in preclinical models 9
• Represents a novel technological approach but remains investigational

Pan-RAS Inhibitors:

• Daraxonrasib (RMC-6236): A pan-RAS inhibitor targeting all ON-state RAS proteins, currently in phase III trials for NSCLC and pancreatic cancer 10, 11
• Would theoretically cover G12V mutations but lacks approval

PROTAC Molecules:

• Setidegrasib (ASP3082): Targets KRAS G12D specifically, not G12V 10, 11

Peptide-Based Inhibitors:

• Novel KRAS G12V-targeting peptides showing antiproliferative activity in colorectal cancer cell lines, but purely preclinical 12

Clinical Management Algorithm

1. Confirm mutation status via comprehensive NGS testing to rule out other targetable alterations
2. Initiate standard chemotherapy appropriate for tumor type:
   • NSCLC: Platinum doublet ± immunotherapy 1, 3
   • Colorectal: FOLFOX/FOLFIRI ± bevacizumab 2
3. Avoid ineffective targeted therapies:
   • Do not use KRAS G12C inhibitors 1
   • Do not use anti-EGFR antibodies in any KRAS-mutant disease 4, 5
4. Consider clinical trial enrollment for investigational G12V-targeting agents 10, 11

Critical Pitfalls to Avoid

• Do not prescribe sotorasib or adagrasib for G12V mutations—they are mutation-specific for G12C only and will not provide benefit 1, 6
• Do not use cetuximab or panitumumab in any KRAS-mutant colorectal cancer, including G12V 4, 2
• Do not delay standard chemotherapy while waiting for investigational agents that may never materialize

The development of G12V-specific inhibitors remains an active area of research, with multiple mechanisms under investigation including RNAi, pan-RAS inhibition, and novel small molecules 9, 10, 11, 13, 12. However, none have achieved regulatory approval, and patients require standard cytotoxic chemotherapy as the evidence-based treatment.